#1Admit PHILIPS, GERARD MARL Adult ECG HR IRADIMED Investor Presentation November 3, 2023 IRADIMED Innovators in MRT Patient Care 1 12:35:55 INNOVATORS IN MRI PATIENT CARE 3885T MRI Remote Tablet Display 1111 160 50 Pl. Sp02 3.1 75 % PR 100-75 mmHg Resp CO2 50 15 38 10 30 ppm rpm bpm 2N % Temp °F NIBP mmHg EV ISO 160 143 21 #22 98.6 120/80 (90) 50 1.3 INSP 1.2 Auto 2:20 Cuff 0 MR MR CONDITIONAL SETTINGS ALARM OFF TREND RECORD NSP KEDUTHOR AD GAUSS AUDIO ALARM OFF SILENCE POWER MAGNETIC HELD UM APREP#22 Forward-Looking Statements This presentation contains a preliminary financial outlook for the full year 2023 and other forward-looking statements (i.e., statements that are not historical facts). Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made, which reflect management's current estimates, projections, expectations, or beliefs, and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, impacts of the COVID-19 pandemic, including the impact of existing and new variants, and measures taken in response; potential disruptions in our limited supply chain for our products; the Company's ability to receive FDA 510(k) clearance for new products and product candidates; unexpected costs, delays or diversion of management's attention associated with the design, manufacture or sale of new products; the Company's ability to implement successful sales techniques for existing and future products and evaluate the effectiveness of its sales techniques; additional actions, warnings or requests from the FDA or other regulatory bodies; our significant reliance on a limited number of products; a reduction in international distribution; actions of the FDA or other regulatory bodies that could delay, limit or suspend product development, manufacturing or sales; the effect of recalls, patient adverse events or deaths on our business; difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services; changes in laws and regulations or in the interpretation or application of laws or regulations. Further information on these and other factors that could affect the Company's financial results is included in filings we make with the Securities and Exchange Commission from time to time. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements. IRADIMED#33 We Are MRI PATIENT CARE IRADIMED TANDAAN ATMONG 1.43 OR NOD NEW #182 1880 " 13 75 100-75 38 10 98.6 120/80 (90) Non-Magnetic • ● Portable MRI IV Infusion Pump Portable MRI Patient Monitor • MRI Room Entry Safety - FMD IRADIMED Innovators in MRI Patient Care#44 iRadimed Timeline Susi and his Invivo team develop specialized wireless technology in MRI with the 3150 Omni-Trak Susi founds Iradimed after the sale of Invivo and develops the world's 1st MRI- compatible IV 1987 Roger Susi founds Invivo Research, and develops the world's 1st MRI patient monitor, the 3100 Omni-Trak 1996 www pump, the 3850 2005 2012 Iradimed begins selling the 2nd gen 3860 IV 100 TH 99 Sp 97 pump through a direct sales force 70 75 10075 120/80190) IRMD Initial Public Offering on Nasdaq 2014 HAPPY LISTING ANNIVERSARY 2014-2019 IRADIMED IRMD Nasdaq Listed Nasdaq 2016 The IRadimed 3880 1st non-magnetic patient monitoring solution, designed to move with the patient between their care unit and the MRI suite while safely maintaining the 'continuity of care' IRadimed 3870 Next- Gen IV infusion pump slated to be released to the market in late 2024 - early 2025. 2023 IRADIMED#5MRI Environment Challenge FDA Reported MRI Adverse Event Types¹ Image Quality Unclear Acoustic 4% Misc. 6% 6% 6% Equipment Risks Ferrous components create hazards ⚫ Device performance altered by magnetic field ⚫ Burn risk from conductive materials (wire danger) Image artifact interferes with diagnosis - RF noise Projectile 9% Mechanical 11% 5 1: MRI-related FDA Adverse Event Reports: a 10 Year Review, 2019 58% Thermal SIEMENS MAGNETOM Skyra ATm-Dot System IRADIMED#6Technical Expertise and Intellectual Property . 2 B Breakthrough use of piezo ceramic Ultrasonic Motive technique Non-magnetic and RF quiet medical device design MRI wireless connectivity - custom radio design 19 Issued patents and 3 pending patents 1 3 5 6 MRidium" RARI INFUSION SYSTEM 1 17:31:32 UI 6.9 4 << (7) START/STOP CHANNEL B (1) 00 8 Bolus A >>> propofol 10 Lib mg Dose. kg Rate 720 mL/hr Time 00:00:09 UTBI 1.7 Lib Primary B pentobarbital mg Dose4 kghr Rate 30 mLihr Time 03:13:50 UTBI mL 3 mL (11) ch € (12) 97 mL E (13) START/STOP CHANNEL MENU 1 2 3 A 4 5 6 CANCEL 7 C 0 ENTER 6 8 ALARM SILIENCE IRIOvcpment CORPORATION 14 (15) IRADIMED#7IRadimed 3860+ Non-Magnetic IV Infusion Pump System • . • Wireless remote display $14.5M in Sales FY22 (+ 9% YOY) plus $3.5M IV Sets Average mid -70% gross margins Proprietary IV sets provide recurring revenue component Product Opportunity/Growth • No direct competition . Current Install base ~6,600 7 • Initial market assumption based on 1 IV pump for every 1 MRI Discovered opportunity for pumps as workflow solution leads to multiple device orders by customers (multiplier effect) Next generation pump planned for late 2024 -early 2025 Significant replacement opportunity for the new pump as large % of install base will be nearing EOL MRidium 16:12:22 H Prinary A Rate 15.0 UTBI > nl hr 9.1 mL 0.0 mL UI Sp02 96 PR:13 Bolus 2. 65 BPM Channel B B B MRidium" T5 16:12:22 Prinary A > Rate 15.0 L UTBI 9.1 mL UI 8.8 mL Sp02 96% PI: 1.9 Bolus 65 BPM Channel B A 656 B MENU Av (4) 4 ENTER QOOO 000 A . CANCEL SALENCE Radimed B (1) MENU A 45 CANCEL 4 7 . ENTER ALARMA SALENCE Radimed IRADIMED#8MRI Patient Workflow Challenge - Moving Patients Safely 75 Patient Preparation Patient connected to traditional patient monitor and infusion pump Patient Transported to MRI Time consuming equipment changeover or a patient can be unmonitored for several minutes MRI Exam (Competitive View) Large MRI monitor connected to the patient and long IV-line extensions added to IV pumps Patient Transported from MRI Time consuming equipment changeover or a patient can be unmonitored for several minutes Recovery or Critical Care Conventional medical devices are connected to the patient again 100+ lbs. Competitor MRI monitors stay in the MRI room Up to 35 Minutes¹ delayed occlusion alarm & medication from long IV lines Up to 3 Different monitors needed (Bedside, Transport & MRI) 8 1. Deckert. "The Effects of Multiple Infusion Lines Extensions on Occlusion Alarm Function of an Infusion Pump." Anesth Analg. 2009 Feb;108(2):518-20 IRADIMED#9IRadimed 3880 Non-Magnetic Patient Monitor . Only Portable and Non-magnetic MR monitor Highly advanced 'home grown' piezo tech $21M in Sales FY22 (+ 58% YOY) Average mid -70% gross margins Proprietary electrodes and disposables provide recurring revenue component Product Opportunity/Growth • One direct competitor - Invivo/ Phillips Current Install base ~1600 Portability allows for unique solution to MRI workflow challenges and expands market opportunity as seen in the pump market (multiplier effect) 600:00:00 Admit Patient Name Adult ΕΠ 10 mm/mV MRI ECG HR P.L 3.1 MAC % Gas 160 50 75 Sp02 bpm % PR ppm www.100 75 160 Off 160 90 50 CO2 mmHg Resp 30 rpm 50 15 38 10 2 IN mmHg 98.6 120/80 (90) Auto 2:20 Cuff 0 02 N20 SEV % Temp ISO OF NIBP 4.5 40 55 21 ET 22 102.2 96.8 1.3 IN 12 IRADIMED Innovators in MR Patient Care ON/CHARGE SETTINGS PAUSE TREND PRINT NIBP ALARM SILENCE 3880 Muter Monitoring S 9 IRADIMED#10$2.5 B $14B IV Pumps MRI is a Growing Modality 37,845 MRI systems worldwide and 12,623 MRI systems in the U.S.1 99.4MM MRI scans performed annually2 Global Market Opportunity Market Assumptions MRI scanners USA: ~5,700 ROW: ~21,000 Critical care departments USA: ~5,300 ROW: ~19,500 $1.1B Monitors 10 10 1. OECD Health Statistics 2022 12 2. OECD Health Statistics 2022 IRADIMED#1111 Commercial Strategy . Continue expansion of MRI-focused U.S. direct sales force and our international sales efforts 28 U.S. field sales personnel 80+ countries with distribution channels Lead markets via engineering superiority Provide best in class customer service and user experience - 5 U.S. field clinical specialists • Continue to innovate with MRI compatible patient care and safety products FMD (ferromagnetic detection device) IRADIMED#1212 Next Generation IV Pump Replacement Opportunity Next generation pump planned for late 2024 - early 2025 - 510K submission with FDA planned for Q3/Q4 of 2023 Significant replacement opportunity for the new pump as large % of install base will be nearing EOL - - Approximate installed base of +7,500 units by end of 2024 Estimate 4,000 units at or nearing EOL 25% of EOL units = 1,000 units (~2X current IV pump shipments) IRADIMED#1313 BUILDING THE LEADING MRI PATIENT CARE TECHNOLOGY COMPANY Growth Roadmap Fuel Market Penetration Continue to promote hospital MRI pump adoption across all departments Leverage recurring revenue opportunity with disposables - current annual units less than .5% of 99M MRI scans/yr for large growth opportunity. Monitor Market Opportunity Accelerate market share of MRI monitor replacements with superior product Develop market multiplier effect as succeeded with pump market Next Generation Infusion Pump Very Significant pump replacement market with introduction of new pump . Increase International Presence Add dedicated regional sales managers OUS Expand utilization in hospital critical care departments Channel Expansion • Opportunity for monitor growth in U.S. ambulatory imaging centers MRI OEM partnerships with GE, Canon, & Siemens 2022 2025 2X 2022 revenue within 3 years IRADIMED#14Financial Highlights IRMD Revenue (MM) FY Revenue Non GAAP EPS 70M 60M 50M 39M 40M 30M 20M 10M OM 42M 32M 0.85 0.83 2019 Revenue by Type FY22 14 Pump 27% Warranty 4% Disp & Serv 27% 0.40 2020 2021 Monitor 41% Data as of 12/31/2022, FY23 Data guidance provided by Management on 11/3/23 53M 1.06 2022 Average over past 5 years FY23 Guidance: $65.0-65.5M $1.48-1.51 1.4 1.2 1.0 0.8 0.6 90 0.4 2023 FY22 Financial Results 77.4% Gross Margin FY22 29.3% GAAP Op. Margins FY22 $1.10 Adjusted EPS FY22 76.2% Avg Gross Margin $8.2 MM Free cash flow FY22 IRADIMED#1515 Quarterly Revenue & Adjusted Earnings Per Share $18.0 $0.60 $0.55 2023 Financial Guidance $16.0 $16.5 $16.1 $15.5 $0.50 - $14.0 $14.9 $0.45 $13.4 $0.40 $12.0 $12.7 $0.40 $12.3 $11.9 $10.0 $0.33 $0.33 $0.32 $0.30 $0.29 $0.26 $0.35 - $0.30 • $8.0 $0.25 • Q4 2023: . Rev. $16.9MM - $17.4MM Adj. EPS $0.38 - $0.41 Full Year 2023: Rev. $65.0MM - $65.5MM Adj. EPS $1.48-$1.51 $6.0 $0.22 $0.20 $0.15 $4.0 $0.10 $2.0 $0.05 $- Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 IRADIMED#16Company Highlights 16 • Create MRI access for more patients • Prevent projectile and heating risks Customer Value Creation • Accurate IV infusions and patient monitoring Preserve MRI image quality Q1 Financial Highlights 25% YOY Revenue Growth in Q1 23 $.30 Adjusted EPS in Q1 23 • Clinical accuracy in strong magnetic and RF fields Non-magnetic medical device design proprietary novel piezo technology • Technical Expertise • MRI wireless connectivity via in house designs • 19 Issued patents and 3 pending patents . 28 U.S. field sales personnel Robust Distribution Network • 5 U.S. field clinical specialists 80+ countries with distribution channels Growing Technology Adoption 150 ~6.6K IV 65 pumps 75 100 75 38 10 98.4120/80 (90) ~1.6K Monitors Forbes 2023 AMERICA'S BEST SMALL COMPANIES ©2022 FORBES LLC. USED WITH PERMISSION Approx. $55M in Working Capital @Q1 23 No Debt $1.05 per share Special Dividend $6.2M Land Purchase for Future Mfg. Facility Named to Forbes 2023 Best Small Companies in America IRADIMED#1717 IRadimed Leadership Team Roger Susi PRESIDENT AND CHIEF EXECUTIVE OFFICER Jack Glenn CHIEF FINANCIAL OFFICER Steve Kachelmeyer VP OF REGULATORY AND QUALITY ASSURANCE GE Healthcare Lynn Neuhardt VP OF RESEARCH AND DEVELOPMENT icumedical IRADIMED 1 Invivo CHOLESTECH 1 Invivo ekSOBIONICS SOLTAMEDICAL MERZ Hospira IRADIMED#18IRADIMED Innovators in MRI Patient Care 12:35:55 Admit PHILIPS, GERARD Adult 10 mm/mV MRI MAC Gas 02 N20 SEV % Temp ISO 1.43 15 55 2.1 LT 2.2 JASNI 40 55 1.3 1.2 NN OFF TREND RECORD NIBP 3885T MRI Remote Tablet Display ECG HR 160 50 75 P.I. SpO2 % PR 3.1 Off 90 CO2 50 15 10075 mmHg Resp bpm 38 10 30 ET 8 2 N ppm rpm mmHg OF NIBP 160 90 98.6 120/80 (90) Auto 2:20 AUDIO ALARM OFF SILENCE 90 Why IRadimed Disruptive non-magnetic technology addressing a major unmet need Industry leading profitability Numerous growth drivers with innovative product pipeline Established global commercial footprint Proven MedTech management team IRADIMED#19MAC Gas %Temp OF NIBP 02 H20 SEV ISO 15 55 21 22 TOP 12 1.43 98.6120/80 (90) 40 55 1.3 Thank You SETTINGS 50 Auto 2:20 Cuff 0 MR MACONDITIONAL ALARM OFF RENCE KEEP OUTSIDE 75 GAUSS POWER JUST SICHETIC ORDIN MALTES Investor [email protected] ☑IRADIMED Innovators in MRI Patient Care 1 19